|
|
Monoclonal Antibody Therapeutics - Current Market Dynamics & Future OutlookPublished by: AS Insights Published: May. 1, 2005 - 42 Pages Table of Contents1. Executive Briefing 2. Introduction 2.1 Definition & Scope 2.2 Currently Marketed Monoclonal Antibody Therapeutics 3. Market Size & Growth Rates 3.1 Global Market for Monoclonal Antibody Therapeutics 3.2 North American Market for Monoclonal Antibody Therapeutics 3.3 European Market for Monoclonal Antibody Therapeutics 3.4 Factors Driving the Market 3.5 Leading Brands Revenue & Market Share 4. Leading Monoclonal Antibody Therapeutics on the Market 4.1 Remicade (Infliximab) 4.2 Rituxan / MabThera 4.3 Herceptin / Trastuzumab 4.4. Synagis / Palivizumab 4.5 Humira (Adalimumab) 4.6 Avastin (bevacizumab) 4.7 ReoPro (Abciximab) 4.8 Xolair (Omalizumab) 4.9 Campath (Alemtuzumab) 4.10 Orthoclone (OKT3 - muromonab-CD3) 4.11 Raptiva (efalizumab) 4.12 Simulect (Basiliximab) 4.13 Mylotarg (Gemtuzumab ozogamicin) 4.14 Zevalin (Ibritumomab tiuxetan) 4.15 Panorax (Edrecolomab - Mab17-1A) 4.16 Bexxar (Tositumomab) 4.17 Erbitux (Cetuximab) 5. Future Outlook 5.1 Monoclonal Antibody Therapeutics Near Commercialization 5.2 Strategic Discussion 5.3 Monoclonal Antibody Therapeutics Market Forecast List of Tables 1. Global Market for Monoclonal Antibody Therapeutics (2000 - 2004) Market Revenue & Growth Rates 2. Global Market for Monoclonal Antibody Therapeutics - Geographical Segmentation (2004) 3. North American Market for Monoclonal Antibody Therapeutics (2000 - 2004) Market Revenue & Growth Rates 4. European Market for Monoclonal Antibody Therapeutics (2000 - 2004) Market Revenue & Growth Rates 5. Global Market for Monoclonal Antibody Therapeutics (2005 - 2010) Revenue Forecasts 6. Monoclonal Antibody Therapeutics - Leading Brands Market Share (2004) 7. Monoclonal Antibody Therapeutics - Leading Brands Market Revenue (2004) 8. Monoclonal Antibody Therapeutics Available on World Markets (2004) 9. Remicade (Infliximab) (2000 - 2004) Global Revenue & Growth Rates 10. Remicade (Infliximab) (2000 - 2004) North American Market Revenue & Growth Rates 11. Rituxan / MabThera (2000 - 2004) Global Revenue & Growth Rates 12. Rituxan / MabThera (2000 - 2004) North American Market Revenue & Growth Rates 13. Herceptin (Trastuzumab) (2000 - 2004) Global Revenue & Growth Rates 14. Herceptin (Trastuzumab) (2000 - 2004) North American Market Revenue & Growth Rates 15. Synagis (Palivizumab) (2000 - 2004) Global Revenue & Growth Rates 16. Synagis (Palivizumab) (2000 - 2004) North American Market Revenue & Growth Rates 17. Humera (Adalimumab) (2003 - 2004) Global Revenue & Growth Rates 18. Humera (Adalimumab) (2003 - 2004) North American Market Revenue & Growth Rates 19. ReoPro (Abciximab) (2000 - 2004) Global Revenue & Growth Rates 20. ReoPro (Abciximab) (2000 - 2004) North American Market Revenue & Growth Rates 21. Xolair (Omalizumab) (2003 - 2004) Global Revenue & Growth Rates 22. Xolair (Omalizumab) (2003 - 2004) North American Market Revenue & Growth Rates 23. CamPath (Alemtuzumab) (2000 - 2004) Global Revenue & Growth Rates 24. CamPath (Alemtuzumab) (2000 - 2004) North American Market Revenue & Growth Rates AbstractThe global market for Monoclonal Antibody (Mab) Therapeutics reached a total of $11.2 billion in 2004. The market has been growing at an impressive compound average annual growth rate of 42% over the previous five years.The key advantage of Mab Therapeutics is their high levels of specificity for the relevant disease targets. This pinpoint specificity also serves to prevent harm to healthy cells and, hence, typically results in fewer adverse effects compared to other medicines. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||